Latest Biopharmaceuticals News

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Clinuvel Pharmaceuticals targets year-end for topline results from its pivotal vitiligo trial of SCENESSE® combined with narrowband UVB, aiming to expand the drug's use beyond its current rare disease indication.

Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.

CLINUVEL Pharmaceuticals is relocating its corporate headquarters to the United States and reducing its global workforce by up to 20%, realigning its operations to focus solely on the US pharmaceutical market and unlock greater capital access.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Telix Pharmaceuticals reported a 21% year-on-year revenue jump to US$247 million in Q2 2026, buoyed by strong Precision Medicine sales and a new Regeneron partnership. The company also secured FDA alignment on a pivotal prostate cancer trial and expanded its manufacturing footprint.

Immuron Limited reported a 6% increase in FY26 sales to AUD 7.7 million, driven by strong gains in Canada and the US despite mixed Australian performance. Marketing initiatives and retail expansion underpin growth.

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Neurotech International has secured FDA clearance for its Investigational New Drug application for NTI164, enabling clinical development in the US and advancing its global registration and commercialisation plans.

Argent BioPharma has struck a global licensing deal for its CannEpil® epilepsy therapy with Splash Beverage Group, securing US$5.5 million upfront through convertible debt forgiveness and retaining manufacturing and intellectual property rights alongside a 15% royalty on future sales.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.